Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

Oxurion misses in macular edema trial
Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317 plus Lucentis ranibizumab did not improve mean Best Corrected Visual Acuity (BCVA) at three months, the primary endpoint in a single-blind European Phase II trial in 70 patients with diabetic macular edema. THR-317 is a recombinant human mAb against PGF; Lucentis is a humanized mAb fragment against VEGF-A.

Investigator suspends Phase III pancreatic cancer study of NuCana's Acelarin
NuCana plc (NASDAQ:NCNA) said that following a prespecified futility analysis, an independent investigator suspended enrollment of a Phase III study of Acelarin to treat metastatic pancreatic cancer. The investigator said imbalances among prognostic factors and survival trends among subgroups support further analysis of the study's data. The study's primary endpoint evaluated the risk of death among patients receiving gemcitabine vs. those receiving Acelarin, which is a modified version of gemcitabine...